Allogeneic Cell Therapy
Allogeneic Cell Therapy involves the transfer of cells from one person to another for therapeutic purposes. It is much more complicated compared to autologous cell therapy, as problems such as donor availability, rejections, and the need for immunosuppression come hand in hand with it. However, with scientific discoveries dedicated to solving these problems, allogeneic cell therapy is a much more promising therapy, as compared to autologous cell therapy, because of its sustainability. With the right platform and technological improvements, allogeneic cell therapy can be administered to billions of patients worldwide using cells from a couple of hundred donors only.
Esco VacciXcell offers a platform for the mass production of bone marrow-derived and adipose-derived stem cells, intended for allogeneic cell therapy. This platform begins with the mass production of cells using VacciXcell’s TideCell® System; the cells are then harvested using Esco VacciXcell’s TideCell® Cell Harvesting System and filled in ready-to-use nested vials, syringes or cartridges using VacciXcell’s AseptiCell™.
Esco VacciXcell’s allogeneic cell therapy platform offers several advantages over other systems such as cell factories and microcarrier technology, including the reduction in space, unit operation, and labor, low shear stress and passage number. Lower shear stress is desired, as shear stress causes cell death, while lower passaging is advantageous, as passaging increases the risk of the cells changing their structure and losing their integrity. VacciXcell’s platform can be used to produce a trillion cells (1012) within 3 passages, using only thirteen (13) bioreactor systems in just three (3) hours! A trillion cells is a reasonable number to produce 4,000 doses to reduce the manufacturing cost to below USD 2,000/dose per batch (estimating by 5 million cells/kg with average of 50 kg patient - 2.5x108 cells/dose).